News
Public · Published
AVBP: ARR-217 achieved a 44.8% ORR at 6 mg/kg in heavily pretreated metastatic CRC
ArriVent Biopharma reported that ARR-217 achieved a 44.8% objective response rate and 93.1% disease control rate at 6 mg/kg in heavily pretreated metastatic colorectal cancer, with mostly low-grade toxicity and 2% Grade 3 diarrhea.
Published:
Updated:
What happened
ArriVent Biopharma reported that ARR-217 achieved a 44.8% objective response rate and 93.1% disease control rate at 6 mg/kg in heavily pretreated metastatic colorectal cancer, with mostly low-grade toxicity and 2% Grade 3 diarrhea.
Confirmed
Global impact / market context
Positive early data could make ARR-217 a valuable treatment candidate in colorectal cancer, a large market. ArriVent must still fund Phase Ib studies and a planned Phase III trial, so success would affect future capital spending and potential revenue.
Analyst inference
The results are early-stage, from a small study with Phase III start targeted by end-2027, so they carry high development risk. Investors weigh promising response rates against the long, costly path to approval and commercial competition.
Analyst inference
What to watch
- Phase Ib monotherapy and combination studies are continuing, which means researchers are still testing dosing and pairing ARR-217 with other treatments before larger trials. Confirmed
- ArriVent targets starting a Phase III trial by end-2027, which means a large late-stage study to confirm benefits before seeking regulatory approval. Proposed
- Watch for updated efficacy and safety data from ongoing Phase Ib studies, since durable responses and manageable side effects would support moving ARR-217 into Phase III. Analyst inference
Evidence
- Original source link unavailable